PMID- 37665081
OWN - NLM
STAT- MEDLINE
DCOM- 20240328
LR  - 20240328
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 33
IP  - 3
DP  - 2024 Mar
TI  - LncRNA-LINC00472 suppresses the malignant progression of non-small cell lung 
      cancer via modulation of the miRNA-1275/Homeobox A2 axis.
PG  - 283-297
LID - 10.17219/acem/168431 [doi]
AB  - BACKGROUND: Long non-coding RNAs (lncRNAs) are increasingly observed as 
      regulatory factors for the initiation and progression of varying kinds of 
      cancers. However, studies on lncRNAs in non-small cell lung cancer (NSCLC) 
      progression are currently lacking. OBJECTIVES: We intended to determine the role 
      of lncRNA LINC00472 and its downstream regulatory mechanism in NSCLC, thus 
      providing novel ideas for targeted therapies for NSCLC. MATERIAL AND METHODS: The 
      target signaling axis comprising the lncRNA/microRNA/mRNA was identified through 
      bioinformatics analysis. Subcellular localization of LINC00472 was assessed with 
      fluorescence in situ hybridization (FISH). Cellular function experiments were 
      conducted to examine the proliferation, migration, invasion, and apoptosis of 
      NSCLC cells, and dual-luciferase and RNA binding protein immunoprecipitation 
      assays were performed to validate the binding relationship. Quantitative 
      real-time polymerase chain reaction (qPCR) and western blot were utilized to 
      assess the expression levels of the investigated gene and protein, respectively. 
      RESULTS: The LINC00472 expression was markedly decreased in NSCLC tissues and 
      cells. The FISH, combined with nuclear-cytoplasm separation assay, demonstrated 
      that LINC00472 was mainly located in the cytoplasm. The overexpression of 
      LINC00472 restrained proliferation and metastasis of NSCLC in vitro. The 
      LINC00472 could target and repress miR-1275 level, and overexpression of 
      LINC00472 reduced the miR-1275-dependent malignant cell phenotype in NSCLC. 
      Further study revealed that HOXA2 was a downstream target of miR-1275 and was 
      negatively modulated by miR-1275. Rescue assays exhibited that the overexpression 
      of miR-1275 or inhibition of HOXA2 reversed the impact of LINC00472 
      overexpression on the malignant progression of NSCLC cells. The LINC00472 
      repressed the epithelial-mesenchymal transition (EMT) of NSCLC cells through 
      miR-1275/HOXA2. CONCLUSIONS: The LINC00472 functioned as a competing endogenous 
      RNA to modulate HOXA2 level by sponging miR-1275 in NSCLC. Simultaneously, the 
      LINC00472/miR-1275/HOXA2 axis may be a possible therapeutic target and biomarker 
      for NSCLC.
FAU - Jiang, Meichen
AU  - Jiang M
AD  - Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, China.
FAU - Ye, Xiangli
AU  - Ye X
AD  - Department of Respiration Medicine, Fujian Medical University Union Hospital, 
      Fuzhou, China.
FAU - Shi, Dongliang
AU  - Shi D
AD  - Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, China.
FAU - Lin, Qili
AU  - Lin Q
AD  - Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, China.
FAU - Huang, Feijian
AU  - Huang F
AD  - Department of Respiration Medicine, Fujian Medical University Union Hospital, 
      Fuzhou, China.
FAU - Li, Yong
AU  - Li Y
AD  - Department of Respiration Medicine, Fujian Medical University Union Hospital, 
      Fuzhou, China.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (MIRN1275 microRNA, human)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/genetics
MH  - *MicroRNAs/genetics
MH  - *RNA, Long Noncoding/genetics
MH  - *Lung Neoplasms/genetics
MH  - Genes, Homeobox
MH  - In Situ Hybridization, Fluorescence
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Cell Movement/genetics
OTO - NOTNLM
OT  - HOXA2
OT  - LINC00472
OT  - NSCLC
OT  - malignant progression
OT  - miR-1275
EDAT- 2023/09/04 12:42
MHDA- 2024/03/28 06:44
CRDT- 2023/09/04 07:13
PHST- 2022/06/29 00:00 [received]
PHST- 2023/06/16 00:00 [accepted]
PHST- 2024/03/28 06:44 [medline]
PHST- 2023/09/04 12:42 [pubmed]
PHST- 2023/09/04 07:13 [entrez]
AID - 10.17219/acem/168431 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2024 Mar;33(3):283-297. doi: 10.17219/acem/168431.